Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Sternberg

Showing results (421-430 of 564) with videos related to

Pageof 57
Sort By:
European Urology|May 23, 2018
Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled AnalysisMaxine Sun, Lorenzo Marconi, Tim Eisen, et al.
Clinical Genitourinary Cancer|November 12, 2024
Avelumab First-Line Maintenance for Locally Advanced or Metastatic Urothelial Carcinoma: Results From the Real-World US PATRIOT-II StudyPetros Grivas, Pedro Barata, Helen Moon, et al.
European Journal of Cancer (Oxford, England : 1990)|September 9, 2020
Safety and efficacy of atezolizumab in patients with autoimmune disease: Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinomaYohann Loriot, Cora N Sternberg, Daniel Castellano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2024
TROPHY-U-01 Cohort 2: A Phase II Study of Sacituzumab Govitecan in Cisplatin-Ineligible Patients With Metastatic Urothelial Cancer Progressing After Previous Checkpoint Inhibitor TherapyDaniel P Petrylak, Scott T Tagawa, Rohit K Jain, et al.
British Journal of Cancer|January 20, 2022
Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinomaKyrillus S Shohdy, Dario M Villamar, Yen Cao, et al.
British Journal of Cancer|February 20, 2015
IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinomaC-F Xu, T Johnson, J Garcia-Donas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 24, 2017
A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapyK Fizazi, A Ulys, L Sengeløv, et al.
The New England Journal of Medicine|October 1, 2019
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate CancerRonald de Wit, Johann de Bono, Cora N Sternberg, et al.
The New England Journal of Medicine|May 30, 2020
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate CancerCora N Sternberg, Karim Fizazi, Fred Saad, et al.
Frontiers in Oncology|November 17, 2022
Case report: Metastatic urothelial cancer with an exceptional response to immunotherapy and comprehensive understanding of the tumor and the tumor microenvironmentCora N Sternberg, Nara Shin, Konstantin Chernyshov, et al.
Pageof 57

Showing results (421-430 of 564) with videos related to

Sort By:
Pageof 57
European Urology|May 23, 2018
Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled AnalysisMaxine Sun, Lorenzo Marconi, Tim Eisen, et al.
Clinical Genitourinary Cancer|November 12, 2024
Avelumab First-Line Maintenance for Locally Advanced or Metastatic Urothelial Carcinoma: Results From the Real-World US PATRIOT-II StudyPetros Grivas, Pedro Barata, Helen Moon, et al.
European Journal of Cancer (Oxford, England : 1990)|September 9, 2020
Safety and efficacy of atezolizumab in patients with autoimmune disease: Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinomaYohann Loriot, Cora N Sternberg, Daniel Castellano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2024
TROPHY-U-01 Cohort 2: A Phase II Study of Sacituzumab Govitecan in Cisplatin-Ineligible Patients With Metastatic Urothelial Cancer Progressing After Previous Checkpoint Inhibitor TherapyDaniel P Petrylak, Scott T Tagawa, Rohit K Jain, et al.
British Journal of Cancer|January 20, 2022
Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinomaKyrillus S Shohdy, Dario M Villamar, Yen Cao, et al.
British Journal of Cancer|February 20, 2015
IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinomaC-F Xu, T Johnson, J Garcia-Donas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 24, 2017
A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapyK Fizazi, A Ulys, L Sengeløv, et al.
The New England Journal of Medicine|October 1, 2019
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate CancerRonald de Wit, Johann de Bono, Cora N Sternberg, et al.
The New England Journal of Medicine|May 30, 2020
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate CancerCora N Sternberg, Karim Fizazi, Fred Saad, et al.
Frontiers in Oncology|November 17, 2022
Case report: Metastatic urothelial cancer with an exceptional response to immunotherapy and comprehensive understanding of the tumor and the tumor microenvironmentCora N Sternberg, Nara Shin, Konstantin Chernyshov, et al.
Pageof 57